Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | MDM4 | O15151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346077 | 0.83 | KMT2A (0.52) | KMT2AEPHX2MDM4TP53POLB | |
| SCHEMBL24660367 | 0.82 | KMT2A (0.54) | KMT2AEPHX2POLBGAA | |
| SCHEMBL30242843 | 0.80 | KMT2A (0.60) | KMT2AEPHX2MDM4TP53DPP8 | |
| SCHEMBL3727338 | 0.80 | KMT2A (0.60) | KMT2AEPHX2MDM4TP53DPP8 | |
| SCHEMBL10015137 | 0.80 | KMT2A (0.49) | KMT2AEPHX2MDM4TP53POLB | |
| SCHEMBL14363811 | 0.79 | KMT2A (0.44) | KMT2AEPHX2OPRD1 | |
| SCHEMBL18258305 | 0.77 | EPHX2 (0.48) | KMT2AEPHX2GAA | |
| SCHEMBL14603527 | 0.76 | HCAR3 (0.38) | KMT2APOLBGAA | |
| SCHEMBL13349297 | 0.75 | KMT2A (0.50) | KMT2AEPHX2POLB | |
| SCHEMBL1509167 | 0.74 | GAA (0.41) | KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46171-E1 | Functional biopolymer modification reagents and uses thereof | SOLULINK, INCORPORATED (US) | 2016-10-04 | — | — | US | disclosed |
| US-7732628-B2 | Such as 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]benzaldehyde, 4-[8-(2-cyanoethyl-N,N-diisopropylphosphoramidyloxy)-2-aza-1-oxooct-1-yl]acetophenone; for incorporation into oligonucleotides during immobilization and conjugation of biopolymers in solid phase synthesis | SOLULINK INCORPORATED (US) | 2010-06-08 | — | — | US | disclosed |
| US-7102024-B1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2006-09-05 | — | — | US | disclosed |
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203289-A1 | Functional biopolymer modification reagents and uses thereof | OGG1, OGA, HMOX2 | KMT2A 452/4885EPHX2 434/4885MDM4 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.